Bedrijfsoverzicht
Ocugen, Inc. is a biopharmaceutical enterprise dedicated to the discovery, development, and commercialization of novel gene and cell therapies, biologics, and vaccines designed to enhance patient health outcomes. The company operates within the Healthcare sector, specifically inside the Biotechnology industry, a field characterized by high research and development costs and a focus on innovative medical treatments. According to available data, the entity maintains a market capitalization of $577.10 million, generates annual revenue of $4.41 million, and employs a workforce of 116 individuals. These financial figures indicate that the company operates with a relatively small market footprint and limited revenue base, which is typical for early-stage or pipeline-focused biotechnology firms that are allocating capital toward future product launches rather than current commercial sales volume.
Financiële gezondheid
The company reported a revenue of $4.41 million over the trailing twelve months, while its net income stood at -$67,846,000 and EBITDA was -$61,191,000. The substantial disparity between the positive revenue of $4.41 million and the significant negative net income reveals a cost structure where expenses, likely dominated by research, development, and operational overhead, vastly exceed the current sales generated. Free cash flow is reported at -$33,116,000, indicating that the company is currently burning cash and lacks immediate financial flexibility to fund operations without external capital injections or dilution. The margins presented a complex picture, with a gross margin of 0.0%, an operating margin of 8558.5%, and a profit margin of 0.0%. The zero gross margin suggests that the cost of goods sold currently equals total revenue, while the anomalous operating margin figure reflects the specific accounting treatment of the company's losses relative to its revenue base. Regarding liquidity, the company holds $18.57 million in cash against $33.14 million in debt, resulting in a debt-to-equity ratio that is listed as N/A. The current ratio stands at 1.06, which indicates that the company's short-term assets are only slightly higher than its short-term liabilities, suggesting a tight but technically solvent liquidity position. Return on Equity is calculated at -776.9% and Return on Assets at -63.1%, metrics that reveal management is currently generating significant losses on the capital invested by shareholders and utilized in assets.
Waarderingsbeoordeling
Valuation metrics for Ocugen show a trailing P/E ratio of N/A due to negative earnings, while the forward P/E is listed at 40.00. The absence of a trailing P/E combined with a forward P/E implies that the market is attempting to value the company based on future expected earnings rather than current profitability, though the forward multiple is high relative to the current price-to-sales ratio. The price-to-book ratio is -45.13, a figure that indicates the market is pricing the company at a significant negative premium relative to its book value, a common characteristic for biotechnology firms with substantial intangible assets or accumulated deficits. Alternative valuation metrics such as the price-to-sales ratio of 130.77 and an EV/EBITDA of -9.67 suggest that the market is assigning a high multiple to the company's sales, reflecting the potential value of the pipeline despite current cash burn. The stock's 52-week high is $2.73 and the 52-week low is $0.64, placing the current trading price within a wide historical range that reflects high investor sentiment volatility. The beta value is 2.81, which means the stock's price volatility is significantly higher than the broader market, moving with a magnitude nearly three times that of the general index.
Growth & Income
Growth metrics for Ocugen indicate that revenue growth year-over-year is N/A and earnings growth year-over-year is N/A. The lack of comparable growth data suggests the company is in a phase where establishing a revenue baseline is the primary objective rather than expanding a mature sales stream. As the company does not pay a dividend, with a dividend yield of N/A and a payout ratio of 0.0%, it is not distributing earnings to shareholders but instead reinvesting all available capital back into its research and development activities. This strategy aligns with the typical lifecycle of a biotechnology company that prioritizes the advancement of its gene therapy pipeline over providing current income to investors. Consequently, the overall growth and income profile is defined entirely by potential future product commercialization rather than current profitability or dividend distribution, leaving the income profile non-existent in the short term.